In January, we announced our new strategic partnership with Bruker to broaden access to our leading proteomics services & tools for biopharma and #biomarker customers.

In this exciting SpotLight episode, Biognosys’ CEO Oliver Rinner and Rohan Thakur, President of the Bruker Life-Science Mass Spectrometry division, discuss the many synergies of the new alliance and give an outlook of what the future might hold.

The brochure provides you with an overview of Biognosys’ history, including major milestones, our technology, as well as key facts about our offerings.

Download media kit

This comprehensive brochure provides an overview of our services, software, and kits offering.

Download Brochure

E-Poster #MP 033 presented at ASMS 2021

Presenter: Fabio Sabino
Session: Data-Independent Acquisition
Date: Monday, November 1

Lidia Wrobel, Sandra M. Hill, Alvin Djajadikerta, Marian Fernandez-Estevez, Cansu Karabiyik, Avraham Ashkenazi, Victoria J. Barratt, Eleanna Stamatakou, Anders Gunnarsson, Timothy Rasmusson, Eric W. Miele, Nigel Beaton, Roland Bruderer, Yuehan Feng, Lukas Reiter, M. Paola Castaldi, Rebecca Jarvis, Keith Tan, Roland W. Bürli & David C. Rubinsztein. Nature Communications

Enhancing the removal of aggregate-prone toxic proteins is a rational therapeutic strategy for a number of neurodegenerative diseases, especially Huntington’s disease and various spinocerebellar ataxias. This study shows how a compound binding to VCP D1 ATPase enhances proteasomal neurotoxic protein clearance. Furthermore, our proprietary High-Resolution Limited Proteolysis (HR-LiP) technology was used to 3D-map the binding site of the compound under investigation for potential use in neurodegenerative diseases. As a result, we could confidently validate the binding site on the target and explain the observed phenotype.

View Publication

This joint webinar with ETH Zurich features Prof. Dr. Paola Picotti, scientific advisor of Biognosys and inventor of the LiP-MS technology. In the first part of the webinar, Prof. Picotti provides an overview on the development of the LiP-MS workflow in her laboratory starting from the concept of detecting protein structural alterations in complex matrices to its various applications in addressing biological questions such as metabolite-protein interactions, protein aggregation and thermal stability. In the second part of this webinar, Biognosys’ senior scientist Dr. Nigel Beaton focuses on establishing a machine learning-based LiP-MS workflow for the deconvolution of small molecule drug targets in an unbiased manner.

Presenter: Yuehan Feng

Date: Monday, Sep 18, 2023, 11:45 AM – 1:00 PM
Session: PP01

Presenter: Yuehan Feng
In collaboration with Cedilla Therapeutics and the University of Cambridge

Presenter: Amaury Lachaud

Date: Monday, Sep 18, 2023, 11:45 AM – 1:00 PM
Session: PP01

New: Spectronaut^® 19

Unlock Your Data's True Story

New: Spectronaut^® 19

Unlock Your Data's True Story

Learn More